Press release

Vifor Fresenius Medical Care Renal Pharma: Expansion of product portfolio and establishment of a marketing and sales organisation in Europe 

Thursday, 28 May 2015, ↓ directly to download

Galenica and Fresenius Medical Care further develop their common company Vifor Fresenius Medical Care Renal Pharma. The company, which specialises in nephrology medicines, is to expand its product portfolio and substantially further develop its sales and marketing organisation for nephrology medicines in Europe.

Vifor Fresenius Medical Care Renal Pharma, which specialises in nephrology medicines, is expanding its product portfolio. In addition to the iron replacement products Ferinject® and Venofer® for use in nephrology indications as well as the phosphate binder Velphoro®, the company will acquire nephrology medicines commercialised by Fresenius Medical Care, including the phosphate binders Osvaren® and Phosphosorb®. The transfer of the marketing rights is to be completed by the end of 2015. The parties have agreed not to disclose the financial aspects of the agreement.

This portfolio, along with the EU marketing authorisation granted for Velphoro® in August 2014, means Vifor Fresenius Medical Care Renal Pharma now has the critical mass to substantially further develop its sales and marketing organisation in key European markets.

In 2007, Galenica and Fresenius Medical Care entered into a strategic agreement to market and distribute the iron replacement products Venofer® and Ferinject® in Europe, the Middle East, Africa and Latin America for use in dialysis. The common company Vifor Fresenius Medical Care Renal Pharma was established in 2010. The planned expansion of activities represents a further step forward in a successful partnership with the common aim of improving the lives of patients around the world with chronic kidney disease (CKD).

Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world.

Contact

Beatrix Benz

Head of Global Communications & Public Affairs


Vifor Pharma Ltd.

Global Communications
Flughofstrasse 61
P.O. Box
CH-8152 Glattbrugg

Phone:
+41 58 851 80 00
Fax:
+41 58 851 80 01

Send link

Send as link



Links